New York City Delays Enforcement Date for AEDT Law and Issues “Final Rule”
Client Alert | 1 min read | 04.06.23
Today, the New York City Department of Consumer and Worker Protection (“DCWP”) announced the “Final Rule” for the New York AEDT law (Local Law 144), and stated that the enforcement date is moved back from April 15, 2023, to July 5, 2023.
This is the second time the DCWP has changed the enforcement date for New York’s new AEDT law, which requires companies that use an automated employment decision tool to conduct a bias audit and notify job candidates. Crowell has monitored the law’s progress since last year.
In addition to pushing back the enforcement date by approximately ten weeks, the DCWP issued new rules that it states define terms and clarify requirements related to the bias audit, publishing results, and notice. The changes include:
- Modifying the definition of “machine learning, statistical modeling, data analytics, or artificial intelligence.” The DCWP specifically states that the modification “expand[s]” the scope of this definition;
- Adding a new requirement that the number of individuals in the “unknown” category must be stated in the summary results;
- Allowing the auditor to exclude a category that comprises less than 2% of the data being used for the bias audit from the calculations of impact ratio;
- Clarifying when an employer or agency may rely on a bias audit using another’s historical data;
- Clarifying that the number of applicants in a category and scoring rate for the category must be included in the summary results.
The notice also provides new examples of how to comply with the law and clarifies existing examples. Crowell will continue to monitor how Local Law 144 progresses over the next ten weeks.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection





